论文部分内容阅读
目的 :探讨HBsAg阳性原发性肝癌 (PHC)和乙肝后肝硬化患者血清IgM型HBcAb测定的临床意义。方法 :采用酶免疫法测定HBsAg阳性PHC组 (40例 )和乙肝后肝硬化组 (45例 )血清IgM型HBcAb的阳性率。结果 :HBsAg阳性PHC组IgM型HBcAb的阳性率 (2 3/40 )明显高于乙肝后肝硬化组 (6 /45 ) ,P <0 .0 0 1,差异有显著性。结论 :血清IgM型HBsAb是HBsAg阳性PHC的肿瘤标记物。
Objective: To investigate the clinical significance of serum IgM type HBcAb in patients with hepatocellular carcinoma (PHC) and hepatitis B cirrhosis. Methods: The positive rates of serum IgM HBcAb in HBsAg positive PHC group (40 cases) and hepatitis B cirrhosis group (45 cases) were determined by enzyme immunoassay. Results: The positive rate of IgM HBcAb in HBsAg positive PHC group (2 3/40) was significantly higher than that in hepatitis B cirrhosis group (6/45), P <0.01, the difference was significant. Conclusions: Serum IgM-type HBsAbs are tumor markers of HBsAg-positive PHC.